2-(Diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-[(4-methoxy-3-methylphenyl)methoxy]-3-isoquinolinecarboxylic acid | 152362-64-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(Diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-[(4-methoxy-3-methylphenyl)methoxy]-3-isoquinolinecarboxylic acid
• 英文别名: 2-Diphenylacetyl-6-methoxy-5-(4-methoxy-3-methyl-benzyloxy)-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid；2-(2,2-diphenylacetyl)-6-methoxy-5-[(4-methoxy-3-methylphenyl)methoxy]-3,4-dihydro-1H-isoquinoline-3-carboxylic acid
• CAS: 152362-64-6
• 化学式: C₃₄H₃₃NO₆
• 分子量: 551.639
• InChiKey: PHKOHUWGKPCJNE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  41
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  85.3
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  (RS)-2-(Diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-[(4-methoxy-3-methylphenyl)methoxy]-3-isoquinolinecarboxylic acid, ethyl ester 、 、 sodium hydroxide 在 甲醇 、 水 、 溶剂黄146 、 silica gel 、 chloroform methanol 作用下， 以 甲醇 为溶剂， 反应 0.25h， 生成 2-(Diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-[(4-methoxy-3-methylphenyl)methoxy]-3-isoquinolinecarboxylic acid
  参考文献：
  名称：

  Substituted 1,2,3,4-tetrahydroisoquinolines with angiotensin II receptor

  摘要：

  本发明涉及新型取代的1,2,3,4-四氢异喹啉，其在治疗血管再狭窄、中枢神经系统的各种疾病、调节女性生殖功能、认知增强、动脉粥样硬化以及治疗过度AVP分泌障碍方面有用。本发明还揭示了用于制备该化合物的新型中间体。还揭示了使用该化合物和含有它们的制药组合物的方法。

  公开号：

  US05489686A1

文献信息

• SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINES WITH ANGIOTENSIN II RECEPTOR ANTAGONIST PROPERTIES
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0641326A1

  公开（公告）日：1995-03-08
• METHOD OF TREATMENT OR PROPHYLAXIS INFLAMMATORY PAIN
  申请人：THE UNIVERSITY OF QUEENSLAND

  公开号：EP1996183A1

  公开（公告）日：2008-12-03
• METHOD OF TREATMENT OR PROPHYLAXIS OF INFLAMMATORY PAIN
  申请人：Smith Maree Therese

  公开号：US20100292159A1

  公开（公告）日：2010-11-18

  This invention discloses the use of angiotensin II receptor 2 (AT 2 receptor) antagonists for the treatment, prophylaxis, reversal and/or symptomatic relief of inflammatory pain, including hyperalgesia, thermal or mechanical allodynia, in vertebrate animals and particularly in human subjects. The AT 2 receptor antagonists may be provided alone or in combination with other compounds such as those that are useful in the control of inflammatory conditions.
• Method of Treatment or Prophylaxis of Inflammatory Pain
  申请人：Spinifex Pharmaceuticals Pty Ltd

  公开号：US20140142116A1

  公开（公告）日：2014-05-22

  A method of treatment, reversal and/or symptomatic relief of inflammatory pain, including hyperalgesia, thermal or mechanical allodynia, in vertebrate animals, particularly in human subjects, comprising administering angiotensin II receptor 2 (AT 2 receptor) antagonists is disclosed. The AT 2 receptor antagonist may be provided alone or in combination with other compounds such as those that are useful in the control of inflammatory pain.
• METHOD OF TREATMENT OR PROPHYLAXIS INFTAMMATORY PAIN
  申请人：Novartis AG

  公开号：US20160052925A1

  公开（公告）日：2016-02-25

  A method of treatment, reversal and/or symptomatic relief of inflammatory pain, including hyperalgesia, thermal or mechanical allodynia, in vertebrate animals, particularly in human subjects, comprising administering angiotensin II receptor 2 (AT 2 receptor) antagonists is disclosed. The AT 2 receptor antagonist may be provided alone or in combination with other compounds such as those that are useful in the control of inflammatory pain.